Clinical and positron emission tomography of Parkinson's disease caused by LRRK2
- PMID: 15732108
- DOI: 10.1002/ana.20401
Clinical and positron emission tomography of Parkinson's disease caused by LRRK2
Abstract
We have recently identified mutations in a gene leucine-rich repeat kinase-2 (LRRK2), which cause autosomal dominant Parkinson's disease. Here, we describe two families with autosomal dominant Parkinson's disease caused by a LRRK2 G2019S mutation. We present here a clinical description of patients, including 6-(18)F-fluoro-L-dopa positron emission tomography and discuss the potential implications of this mutation, which alters a conserved residue in a domain required for kinase activation.
Similar articles
-
Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.Parkinsonism Relat Disord. 2009 Mar;15(3):242-4. doi: 10.1016/j.parkreldis.2008.05.011. Epub 2008 Jul 14. Parkinsonism Relat Disord. 2009. PMID: 18621566
-
G2019S LRRK2 mutation in French and North African families with Parkinson's disease.Ann Neurol. 2005 Nov;58(5):784-7. doi: 10.1002/ana.20636. Ann Neurol. 2005. PMID: 16240353
-
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.Parkinsonism Relat Disord. 2009 May;15(4):277-80. doi: 10.1016/j.parkreldis.2008.06.009. Epub 2008 Sep 20. Parkinsonism Relat Disord. 2009. PMID: 18805725
-
PARK8 LRRK2 parkinsonism.Curr Neurol Neurosci Rep. 2006 Jul;6(4):287-94. doi: 10.1007/s11910-006-0020-0. Curr Neurol Neurosci Rep. 2006. PMID: 16822348 Review.
-
Clinical and pathologic features of families with LRRK2-associated Parkinson's disease.J Neural Transm Suppl. 2006;(70):221-9. doi: 10.1007/978-3-211-45295-0_34. J Neural Transm Suppl. 2006. PMID: 17017533 Review.
Cited by
-
Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila.Hum Mol Genet. 2014 Jun 15;23(12):3157-65. doi: 10.1093/hmg/ddu026. Epub 2014 Jan 23. Hum Mol Genet. 2014. PMID: 24459295 Free PMC article.
-
α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease.Neurotoxicology. 2011 Oct;32(5):622-9. doi: 10.1016/j.neuro.2011.01.003. Epub 2011 Jan 14. Neurotoxicology. 2011. PMID: 21238487 Free PMC article. Review.
-
Neuroprotective Effect of the LRRK2 Kinase Inhibitor PF-06447475 in Human Nerve-Like Differentiated Cells Exposed to Oxidative Stress Stimuli: Implications for Parkinson's Disease.Neurochem Res. 2016 Oct;41(10):2675-2692. doi: 10.1007/s11064-016-1982-1. Epub 2016 Jul 9. Neurochem Res. 2016. PMID: 27394417
-
Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.Neurogenetics. 2009 Oct;10(4):355-8. doi: 10.1007/s10048-009-0186-0. Epub 2009 Mar 13. Neurogenetics. 2009. PMID: 19283415
-
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845. Biomolecules. 2023. PMID: 37238714 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases